Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure
Elevated serum phosphorus, calcium, and fibroblast growth factor 23 (FGF23) levels are associated with cardiovascular disease in chronic renal disease. This study evaluated the effects of sucroferric oxyhydroxide (PA21), a new iron-based phosphate binder, versus lanthanum carbonate (La) and sevelame...
Gespeichert in:
| Veröffentlicht in: | BioMed research international 2015-01, Vol.2015 (2015), p.1-9 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 9 |
|---|---|
| container_issue | 2015 |
| container_start_page | 1 |
| container_title | BioMed research international |
| container_volume | 2015 |
| creator | Funk, Felix Stehle, Jean-Christophe Malluche, Hartmut H. Maillard, Marc Phan, Olivier Burnier, Michel |
| description | Elevated serum phosphorus, calcium, and fibroblast growth factor 23 (FGF23) levels are associated with cardiovascular disease in chronic renal disease. This study evaluated the effects of sucroferric oxyhydroxide (PA21), a new iron-based phosphate binder, versus lanthanum carbonate (La) and sevelamer carbonate (Se), on serum FGF23, phosphorus, calcium, and intact parathyroid hormone (iPTH) concentrations, and the development of vascular calcification in adenine-induced chronic renal failure (CRF) rats. After induction of CRF, renal function was significantly impaired in all groups: uremic rats developed severe hyperphosphatemia, and serum iPTH increased significantly. All uremic rats (except controls) then received phosphate binders for 4 weeks. Hyperphosphatemia and increased serum iPTH were controlled to a similar extent in all phosphate binder-treatment groups. Only sucroferric oxyhydroxide was associated with significantly decreased FGF23. Vascular calcifications of the thoracic aorta were decreased by all three phosphate binders. Calcifications were better prevented at the superior part of the thoracic and abdominal aorta in the PA21 treated rats. In adenine-induced CRF rats, sucroferric oxyhydroxide was as effective as La and Se in controlling hyperphosphatemia, secondary hyperparathyroidism, and vascular calcifications. The role of FGF23 in calcification remains to be confirmed. |
| doi_str_mv | 10.1155/2015/515606 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4499607</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A458161773</galeid><sourcerecordid>A458161773</sourcerecordid><originalsourceid>FETCH-LOGICAL-c594t-7683402c127f9f027d0f3e1f5bda912643f033f5b4d6ec7b647e07f4656b33293</originalsourceid><addsrcrecordid>eNqNkk9vFCEYxidGY5vak3dD4sVo1vKfnYtJs2mtcU2NVa-EZV46NDOwhZna_Wh-Oxm3rtVTucALP548vDxV9Zzgt4QIcUQxEUeCCInlo2qfMsJnknDyeLdmbK86zPkKlzEnEtfyabVHJaVE1Gq_-nniHNgho-jQxWhTdJCSt-j8dtNumhRvfQNoEfu1SdCgIaKlCUNrwtijhUmrGMwAyIQGXcANdKaHdG8_BvS5jXndTsVZ7CHmwWSff1_4brIdOzPxnfXOWzP4GDLyARn0xQzoU2ygm3wt2hRD8fTRNwE26NT4bkzwrHriTJfh8G4-qL6dnnxdnM2W5-8_LI6XMytqPsyUnDOOqSVUudphqhrsGBAnVo2pCZWcOcxYKXkjwaqV5AqwclwKuWKM1uygerfVXY-rHhoLYUim0-vke5M2Ohqv_z0JvtWX8UZzXtcSqyLw6k4gxesR8qB7ny10nQkQx6yJKn-ICVH8IWgxy5SSBX35H3oVxxRKJzSRtVBUCDz_S12aDrQPLhaLdhLVx1yUPBClWKHebKny_zkncLvXEaynmOkpZnobs0K_uN-QHfsnVAV4vQVaHxrzwz9MDQoCztyDhVBzyn4BLUXkVw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1695725508</pqid></control><display><type>article</type><title>Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure</title><source>MEDLINE</source><source>PubMed Central Open Access</source><source>Wiley Online Library Open Access</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Funk, Felix ; Stehle, Jean-Christophe ; Malluche, Hartmut H. ; Maillard, Marc ; Phan, Olivier ; Burnier, Michel</creator><contributor>Paraskevas, Kosmas</contributor><creatorcontrib>Funk, Felix ; Stehle, Jean-Christophe ; Malluche, Hartmut H. ; Maillard, Marc ; Phan, Olivier ; Burnier, Michel ; Paraskevas, Kosmas</creatorcontrib><description>Elevated serum phosphorus, calcium, and fibroblast growth factor 23 (FGF23) levels are associated with cardiovascular disease in chronic renal disease. This study evaluated the effects of sucroferric oxyhydroxide (PA21), a new iron-based phosphate binder, versus lanthanum carbonate (La) and sevelamer carbonate (Se), on serum FGF23, phosphorus, calcium, and intact parathyroid hormone (iPTH) concentrations, and the development of vascular calcification in adenine-induced chronic renal failure (CRF) rats. After induction of CRF, renal function was significantly impaired in all groups: uremic rats developed severe hyperphosphatemia, and serum iPTH increased significantly. All uremic rats (except controls) then received phosphate binders for 4 weeks. Hyperphosphatemia and increased serum iPTH were controlled to a similar extent in all phosphate binder-treatment groups. Only sucroferric oxyhydroxide was associated with significantly decreased FGF23. Vascular calcifications of the thoracic aorta were decreased by all three phosphate binders. Calcifications were better prevented at the superior part of the thoracic and abdominal aorta in the PA21 treated rats. In adenine-induced CRF rats, sucroferric oxyhydroxide was as effective as La and Se in controlling hyperphosphatemia, secondary hyperparathyroidism, and vascular calcifications. The role of FGF23 in calcification remains to be confirmed.</description><identifier>ISSN: 2314-6133</identifier><identifier>EISSN: 2314-6141</identifier><identifier>DOI: 10.1155/2015/515606</identifier><identifier>PMID: 26221597</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Animals ; Body Weight - drug effects ; Calcification ; Carbonates ; Chronic kidney failure ; Colleges & universities ; Comparative analysis ; Coronary vessels ; Disease Models, Animal ; Drug Combinations ; Ferric Compounds - pharmacology ; Ferric Compounds - therapeutic use ; Fibroblast Growth Factors - blood ; Health aspects ; Homeostasis ; Homeostasis - drug effects ; Hydroxides ; Investigations ; Kidney diseases ; Kidney Failure, Chronic - blood ; Kidney Failure, Chronic - complications ; Kidney Failure, Chronic - drug therapy ; Kidney Failure, Chronic - urine ; Lanthanum - pharmacology ; Lanthanum - therapeutic use ; Male ; Metabolism ; Mortality ; Nephrology ; Phosphatase ; Phosphates ; Phosphates - metabolism ; Physiological aspects ; Rats, Wistar ; Rodents ; Sevelamer - pharmacology ; Sevelamer - therapeutic use ; Sucrose - pharmacology ; Sucrose - therapeutic use ; Urine ; Vascular Calcification - blood ; Vascular Calcification - complications ; Vascular Calcification - drug therapy ; Vascular Calcification - urine</subject><ispartof>BioMed research international, 2015-01, Vol.2015 (2015), p.1-9</ispartof><rights>Copyright © 2015 Olivier Phan et al.</rights><rights>COPYRIGHT 2015 John Wiley & Sons, Inc.</rights><rights>Copyright © 2015 Olivier Phan et al. Olivier Phan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2015 Olivier Phan et al. 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c594t-7683402c127f9f027d0f3e1f5bda912643f033f5b4d6ec7b647e07f4656b33293</citedby><cites>FETCH-LOGICAL-c594t-7683402c127f9f027d0f3e1f5bda912643f033f5b4d6ec7b647e07f4656b33293</cites><orcidid>0000-0003-0794-1105</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499607/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499607/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26221597$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Paraskevas, Kosmas</contributor><creatorcontrib>Funk, Felix</creatorcontrib><creatorcontrib>Stehle, Jean-Christophe</creatorcontrib><creatorcontrib>Malluche, Hartmut H.</creatorcontrib><creatorcontrib>Maillard, Marc</creatorcontrib><creatorcontrib>Phan, Olivier</creatorcontrib><creatorcontrib>Burnier, Michel</creatorcontrib><title>Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure</title><title>BioMed research international</title><addtitle>Biomed Res Int</addtitle><description>Elevated serum phosphorus, calcium, and fibroblast growth factor 23 (FGF23) levels are associated with cardiovascular disease in chronic renal disease. This study evaluated the effects of sucroferric oxyhydroxide (PA21), a new iron-based phosphate binder, versus lanthanum carbonate (La) and sevelamer carbonate (Se), on serum FGF23, phosphorus, calcium, and intact parathyroid hormone (iPTH) concentrations, and the development of vascular calcification in adenine-induced chronic renal failure (CRF) rats. After induction of CRF, renal function was significantly impaired in all groups: uremic rats developed severe hyperphosphatemia, and serum iPTH increased significantly. All uremic rats (except controls) then received phosphate binders for 4 weeks. Hyperphosphatemia and increased serum iPTH were controlled to a similar extent in all phosphate binder-treatment groups. Only sucroferric oxyhydroxide was associated with significantly decreased FGF23. Vascular calcifications of the thoracic aorta were decreased by all three phosphate binders. Calcifications were better prevented at the superior part of the thoracic and abdominal aorta in the PA21 treated rats. In adenine-induced CRF rats, sucroferric oxyhydroxide was as effective as La and Se in controlling hyperphosphatemia, secondary hyperparathyroidism, and vascular calcifications. The role of FGF23 in calcification remains to be confirmed.</description><subject>Animals</subject><subject>Body Weight - drug effects</subject><subject>Calcification</subject><subject>Carbonates</subject><subject>Chronic kidney failure</subject><subject>Colleges & universities</subject><subject>Comparative analysis</subject><subject>Coronary vessels</subject><subject>Disease Models, Animal</subject><subject>Drug Combinations</subject><subject>Ferric Compounds - pharmacology</subject><subject>Ferric Compounds - therapeutic use</subject><subject>Fibroblast Growth Factors - blood</subject><subject>Health aspects</subject><subject>Homeostasis</subject><subject>Homeostasis - drug effects</subject><subject>Hydroxides</subject><subject>Investigations</subject><subject>Kidney diseases</subject><subject>Kidney Failure, Chronic - blood</subject><subject>Kidney Failure, Chronic - complications</subject><subject>Kidney Failure, Chronic - drug therapy</subject><subject>Kidney Failure, Chronic - urine</subject><subject>Lanthanum - pharmacology</subject><subject>Lanthanum - therapeutic use</subject><subject>Male</subject><subject>Metabolism</subject><subject>Mortality</subject><subject>Nephrology</subject><subject>Phosphatase</subject><subject>Phosphates</subject><subject>Phosphates - metabolism</subject><subject>Physiological aspects</subject><subject>Rats, Wistar</subject><subject>Rodents</subject><subject>Sevelamer - pharmacology</subject><subject>Sevelamer - therapeutic use</subject><subject>Sucrose - pharmacology</subject><subject>Sucrose - therapeutic use</subject><subject>Urine</subject><subject>Vascular Calcification - blood</subject><subject>Vascular Calcification - complications</subject><subject>Vascular Calcification - drug therapy</subject><subject>Vascular Calcification - urine</subject><issn>2314-6133</issn><issn>2314-6141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNkk9vFCEYxidGY5vak3dD4sVo1vKfnYtJs2mtcU2NVa-EZV46NDOwhZna_Wh-Oxm3rtVTucALP548vDxV9Zzgt4QIcUQxEUeCCInlo2qfMsJnknDyeLdmbK86zPkKlzEnEtfyabVHJaVE1Gq_-nniHNgho-jQxWhTdJCSt-j8dtNumhRvfQNoEfu1SdCgIaKlCUNrwtijhUmrGMwAyIQGXcANdKaHdG8_BvS5jXndTsVZ7CHmwWSff1_4brIdOzPxnfXOWzP4GDLyARn0xQzoU2ygm3wt2hRD8fTRNwE26NT4bkzwrHriTJfh8G4-qL6dnnxdnM2W5-8_LI6XMytqPsyUnDOOqSVUudphqhrsGBAnVo2pCZWcOcxYKXkjwaqV5AqwclwKuWKM1uygerfVXY-rHhoLYUim0-vke5M2Ohqv_z0JvtWX8UZzXtcSqyLw6k4gxesR8qB7ny10nQkQx6yJKn-ICVH8IWgxy5SSBX35H3oVxxRKJzSRtVBUCDz_S12aDrQPLhaLdhLVx1yUPBClWKHebKny_zkncLvXEaynmOkpZnobs0K_uN-QHfsnVAV4vQVaHxrzwz9MDQoCztyDhVBzyn4BLUXkVw</recordid><startdate>20150101</startdate><enddate>20150101</enddate><creator>Funk, Felix</creator><creator>Stehle, Jean-Christophe</creator><creator>Malluche, Hartmut H.</creator><creator>Maillard, Marc</creator><creator>Phan, Olivier</creator><creator>Burnier, Michel</creator><general>Hindawi Publishing Corporation</general><general>John Wiley & Sons, Inc</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0794-1105</orcidid></search><sort><creationdate>20150101</creationdate><title>Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure</title><author>Funk, Felix ; Stehle, Jean-Christophe ; Malluche, Hartmut H. ; Maillard, Marc ; Phan, Olivier ; Burnier, Michel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c594t-7683402c127f9f027d0f3e1f5bda912643f033f5b4d6ec7b647e07f4656b33293</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Animals</topic><topic>Body Weight - drug effects</topic><topic>Calcification</topic><topic>Carbonates</topic><topic>Chronic kidney failure</topic><topic>Colleges & universities</topic><topic>Comparative analysis</topic><topic>Coronary vessels</topic><topic>Disease Models, Animal</topic><topic>Drug Combinations</topic><topic>Ferric Compounds - pharmacology</topic><topic>Ferric Compounds - therapeutic use</topic><topic>Fibroblast Growth Factors - blood</topic><topic>Health aspects</topic><topic>Homeostasis</topic><topic>Homeostasis - drug effects</topic><topic>Hydroxides</topic><topic>Investigations</topic><topic>Kidney diseases</topic><topic>Kidney Failure, Chronic - blood</topic><topic>Kidney Failure, Chronic - complications</topic><topic>Kidney Failure, Chronic - drug therapy</topic><topic>Kidney Failure, Chronic - urine</topic><topic>Lanthanum - pharmacology</topic><topic>Lanthanum - therapeutic use</topic><topic>Male</topic><topic>Metabolism</topic><topic>Mortality</topic><topic>Nephrology</topic><topic>Phosphatase</topic><topic>Phosphates</topic><topic>Phosphates - metabolism</topic><topic>Physiological aspects</topic><topic>Rats, Wistar</topic><topic>Rodents</topic><topic>Sevelamer - pharmacology</topic><topic>Sevelamer - therapeutic use</topic><topic>Sucrose - pharmacology</topic><topic>Sucrose - therapeutic use</topic><topic>Urine</topic><topic>Vascular Calcification - blood</topic><topic>Vascular Calcification - complications</topic><topic>Vascular Calcification - drug therapy</topic><topic>Vascular Calcification - urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Funk, Felix</creatorcontrib><creatorcontrib>Stehle, Jean-Christophe</creatorcontrib><creatorcontrib>Malluche, Hartmut H.</creatorcontrib><creatorcontrib>Maillard, Marc</creatorcontrib><creatorcontrib>Phan, Olivier</creatorcontrib><creatorcontrib>Burnier, Michel</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Middle East & Africa Database</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BioMed research international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Funk, Felix</au><au>Stehle, Jean-Christophe</au><au>Malluche, Hartmut H.</au><au>Maillard, Marc</au><au>Phan, Olivier</au><au>Burnier, Michel</au><au>Paraskevas, Kosmas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure</atitle><jtitle>BioMed research international</jtitle><addtitle>Biomed Res Int</addtitle><date>2015-01-01</date><risdate>2015</risdate><volume>2015</volume><issue>2015</issue><spage>1</spage><epage>9</epage><pages>1-9</pages><issn>2314-6133</issn><eissn>2314-6141</eissn><abstract>Elevated serum phosphorus, calcium, and fibroblast growth factor 23 (FGF23) levels are associated with cardiovascular disease in chronic renal disease. This study evaluated the effects of sucroferric oxyhydroxide (PA21), a new iron-based phosphate binder, versus lanthanum carbonate (La) and sevelamer carbonate (Se), on serum FGF23, phosphorus, calcium, and intact parathyroid hormone (iPTH) concentrations, and the development of vascular calcification in adenine-induced chronic renal failure (CRF) rats. After induction of CRF, renal function was significantly impaired in all groups: uremic rats developed severe hyperphosphatemia, and serum iPTH increased significantly. All uremic rats (except controls) then received phosphate binders for 4 weeks. Hyperphosphatemia and increased serum iPTH were controlled to a similar extent in all phosphate binder-treatment groups. Only sucroferric oxyhydroxide was associated with significantly decreased FGF23. Vascular calcifications of the thoracic aorta were decreased by all three phosphate binders. Calcifications were better prevented at the superior part of the thoracic and abdominal aorta in the PA21 treated rats. In adenine-induced CRF rats, sucroferric oxyhydroxide was as effective as La and Se in controlling hyperphosphatemia, secondary hyperparathyroidism, and vascular calcifications. The role of FGF23 in calcification remains to be confirmed.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>26221597</pmid><doi>10.1155/2015/515606</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-0794-1105</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2314-6133 |
| ispartof | BioMed research international, 2015-01, Vol.2015 (2015), p.1-9 |
| issn | 2314-6133 2314-6141 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4499607 |
| source | MEDLINE; PubMed Central Open Access; Wiley Online Library Open Access; PubMed Central; Alma/SFX Local Collection |
| subjects | Animals Body Weight - drug effects Calcification Carbonates Chronic kidney failure Colleges & universities Comparative analysis Coronary vessels Disease Models, Animal Drug Combinations Ferric Compounds - pharmacology Ferric Compounds - therapeutic use Fibroblast Growth Factors - blood Health aspects Homeostasis Homeostasis - drug effects Hydroxides Investigations Kidney diseases Kidney Failure, Chronic - blood Kidney Failure, Chronic - complications Kidney Failure, Chronic - drug therapy Kidney Failure, Chronic - urine Lanthanum - pharmacology Lanthanum - therapeutic use Male Metabolism Mortality Nephrology Phosphatase Phosphates Phosphates - metabolism Physiological aspects Rats, Wistar Rodents Sevelamer - pharmacology Sevelamer - therapeutic use Sucrose - pharmacology Sucrose - therapeutic use Urine Vascular Calcification - blood Vascular Calcification - complications Vascular Calcification - drug therapy Vascular Calcification - urine |
| title | Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T12%3A43%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20Sucroferric%20Oxyhydroxide%20Compared%20to%20Lanthanum%20Carbonate%20and%20Sevelamer%20Carbonate%20on%20Phosphate%20Homeostasis%20and%20Vascular%20Calcifications%20in%20a%20Rat%20Model%20of%20Chronic%20Kidney%20Failure&rft.jtitle=BioMed%20research%20international&rft.au=Funk,%20Felix&rft.date=2015-01-01&rft.volume=2015&rft.issue=2015&rft.spage=1&rft.epage=9&rft.pages=1-9&rft.issn=2314-6133&rft.eissn=2314-6141&rft_id=info:doi/10.1155/2015/515606&rft_dat=%3Cgale_pubme%3EA458161773%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1695725508&rft_id=info:pmid/26221597&rft_galeid=A458161773&rfr_iscdi=true |